Skip to main content
SpringerLink
Log in

Engineering T-Cell Specificity Genetically to Generate Anti-melanoma Reactivity

  • Protocol
  • First Online:
Methods in Molecular Biology

Part of the book series: Methods in Molecular Biology

Abstract

Melanoma tumors are known to harbor a high number of mutations leading to the expression of neo-antigens which can be recognized by the patient adaptive immune system. In this regard, immunotherapies involving adoptive cell transfer (ACT) of tumor-specific T-cells constitute a promising approach to treat melanoma. However, these cells do not always preexist in the patient or are difficult to isolate and/or expand. Thus, as the specificity of T-lymphocytes is determined by their T-cell receptor (TCR), it is possible to convert peripheral T-cells into cancer specific lymphocytes by transducing them to express a receptor that recognizes a defined tumor epitope. To this end, retroviral vectors can be used to efficiently transduce actively dividing cells such as proliferating T cells, while being relatively safe to the user. As we show herein, this approach is powerful and can be easily implemented, paving the way to the development of advanced research tools and potent clinical immunotherapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Vogelstein B et al (2013) Cancer genome landscapes. Science 339:1546–1558

    Article  PubMed  CAS  ADS  PubMed Central  Google Scholar 

  2. Tran E et al (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641–645

    Article  PubMed  CAS  ADS  Google Scholar 

  3. Robbins PF et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747–752

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P (2013) Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 13:15

    PubMed  PubMed Central  Google Scholar 

  5. Dudley ME et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346–2357

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Haga-Friedman A, Horovitz-Fried M, Cohen CJ (2012) Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity. J Immunol 1950(188):5538–5546

    Article  Google Scholar 

  7. Tal Y et al (2014) An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget 5

    Google Scholar 

  8. Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ (1950) Human T (2013) cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. J Immunol 191:4121–4129

    Article  Google Scholar 

  9. Warnock JN, Daigre C, Al-Rubeai M (2011) Introduction to viral vectors. Methods Mol Biol 737:1–25

    Article  PubMed  CAS  Google Scholar 

  10. Hu WS, Pathak VK (2000) Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev 52:493–511

    PubMed  CAS  Google Scholar 

  11. Wargo JA et al (2009) Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother 58:383–394

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Merhavi-Shoham E, Haga-Friedman A, Cohen CJ (2012) Genetically modulating T-cell function to target cancer. Semin Cancer Biol 22:14–22

    Article  PubMed  CAS  Google Scholar 

  13. Morgan RA et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129

    Article  PubMed  CAS  ADS  PubMed Central  Google Scholar 

  14. Tsukamoto T et al (1999) Isolation of oncogenes from rat mammary tumors by a highly efficient retrovirus expression cloning system. Biochem Biophys Res Commun 265:7–12

    Article  PubMed  CAS  Google Scholar 

  15. Schaft N et al (2003) Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol 1950(170):2186–2194

    Article  Google Scholar 

  16. Kerkar SP et al (2001) Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother 34:343–352

    Article  Google Scholar 

  17. Daniel-Meshulam I, Horovitz-Fried M, Cohen CJ (2013) Enhanced antitumor activity mediated by human 4-1BB-engineered T cells. Int J Cancer 133:2903–2913

    PubMed  CAS  Google Scholar 

  18. Kimizuka F et al (1991) Production and characterization of functional domains of human fibronectin expressed in Escherichia coli. J Biochem (Tokyo) 110:284–291

    CAS  Google Scholar 

  19. Moritz T et al (1996) Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 88:855–862

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Israel Science foundation (1457/12) and the Israel ministry of Health.

Author information

Authors and Affiliations

  1. Laboratory of Tumor Immunology and Immunotherapy, Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, 52900-02, Israel

    Eviatar Weizman & Cyrille J. Cohen

Authors
  1. Eviatar Weizman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cyrille J. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cyrille J. Cohen .

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this protocol

Cite this protocol

Weizman, E., Cohen, C.J. (2015). Engineering T-Cell Specificity Genetically to Generate Anti-melanoma Reactivity. In: Methods in Molecular Biology. Humana Press. https://doi.org/10.1007/7651_2015_297

Download citation

  • DOI: https://doi.org/10.1007/7651_2015_297

  • Published:

  • Publisher Name: Humana Press

Publish with us

Policies and ethics

Search

Navigation